

1. Identification

Product identifier

RELVAR (ROW)/ BREO (US) ELLIPTA

Other means of identification

Synonyms

RELVAR ELLIPTA * BREO ELLIPTA * FLUTICASONE FUROATE/VILANTEROL ELLIPTA * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER (50/25MCG) * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER (100/25MCG)

Recommended use

Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Recommended restrictions

No other uses are advised.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US
5 Moore Drive
Research Triangle Park, NC 27709 USA
US General Information (normal business hours): +1-888-825-5249
Email Address: msds@gsk.com
Website: www.gsk.com
EMERGENCY PHONE NUMBERS -
TRANSPORT EMERGENCIES:
US / International toll call +1 703 527 3887
available 24 hrs/7 days; multi-language response

2. Hazard(s) identification

Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
FLUTICASONE FUROATE	GW685698X * FURAN-2-CARBOXYLIC ACID 6,9-DIFLUORO-17-FLUOROMETHYLSULF ANYLCARBONYL-11-HYDROXY-10,13,16-TRIMETHYL-3-OXO-6,7,8,9,10,11,12,13,14,15,16,17-DODECAHYDRO-3H-CYCLOPENTA(A)PH ENANTHREN-17-YL ESTER * 2080 (GW ACN) * (6ALPHA,11BETA,16ALPHA,17ALPHA)-6,9-DIFLUORO-17-[[[FLUOROMETHYL]THIO]CARBONYL]-11-HYDROXY-16-METHYL-3-OXOANDROSTA-1,4-DIEN-17-YL 2-FURANCARBOXYLATE	397864-44-7	0.4 - 3.2

Chemical name	Common name and synonyms	CAS number	%
MAGNESIUM STEARATE	STEARIC ACID, MAGNESIUM SALT * MAGNESIUM DISTEARATE * DIBASIC MAGNESIUM STEARATE * MAGNESIUM DISTEARATE, PURE	557-04-0	1
VILANTEROL	GW642444M * (ALPHA1-R)-ALPHA1-[[[6-[2-[(2,6-DICHLOR OPHENYL)METHOXY]ETHOXY]HEXYL] AMINO]METHYL]-4-HYDROXY-1,3-BENZE NEDIMETHANOL, TRIPHENYLACETIC ACID SALT * GW642444 TRIPHENYLACETIC ACID SALT	503070-58-4	0.1 - 0.4
Other components below reportable levels			>95.0

*Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

4. First-aid measures

Inhalation	Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
Ingestion	If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control center immediately. Do not induce vomiting without advice from poison control center.
Most important symptoms/effects, acute and delayed	The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; changes in clinical chemistry parameters; headache; inflamed nasal cavity; back pain; changes in blood pressure; altered heart rate and pulse; pain; coughing.
Indication of immediate medical attention and special treatment needed	No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center.
General information	In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media	Water. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
Special protective equipment and precautions for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Fire fighting equipment/instructions	Move containers from fire area if you can do so without risk.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
General fire hazards	No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the SDS.
Methods and materials for containment and cleaning up	Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.
Environmental precautions	Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid prolonged exposure. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

GSK

Components

Type

Value

Note

FLUTICASONE FUROATE
(CAS 397864-44-7)

8 HR TWA

6 mcg/m3

ADE

20 µg/day

OHC

4

REPRODUCTIVE
HAZARD
SKIN

VILANTEROL (CAS
503070-58-4)

15 MIN STEL

20 mcg/m3

8 HR TWA

2 mcg/m3

ADE

5 µg/day

OHC

4

US. ACGIH Threshold Limit Values

Components

Type

Value

MAGNESIUM STEARATE
(CAS 557-04-0)

TWA

10 mg/m3

Biological limit values

No biological exposure limits noted for the ingredient(s).

Exposure guidelines

Appropriate engineering controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

Eye/face protection

If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection

For prolonged or repeated skin contact use suitable protective gloves.

Other

Wear suitable protective clothing as protection against splashing or contamination.

Respiratory protection

No personal respiratory protective equipment normally required. Use a NIOSH/MSHA approved respirator if there is a risk of exposure to dust/fume at levels exceeding the exposure limits.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.

9. Physical and chemical properties

Appearance

Physical state

Solid.

Form

Powder.Inhaler.Coiled blister strip.

Color

Not available.

Odor

Not available.

Odor threshold

Not available.

pH

Not available.

Melting point/freezing point

Not available.

Initial boiling point and boiling range

Not available.

Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	Hazardous polymerization does not occur.
Conditions to avoid	Contact with incompatible materials.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	None known. Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use.
Ingestion	Health injuries are not known or expected under normal use. Expected to be a low ingestion hazard. However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics	The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; changes in clinical chemistry parameters; headache; inflamed nasal cavity; back pain; changes in blood pressure; altered heart rate and pulse; pain; coughing.
--	--

Information on toxicological effects

Acute toxicity

Components	Species	Test Results
FLUTICASONE FUROATE (CAS 397864-44-7)		
Acute		
<i>Inhalation</i>		
LCLo	Rat	> 0.133 mg/l
<i>Oral</i>		
LD50	Mouse	> 2000 mg/kg
	Rat	> 2000 mg/kg

Components	Species	Test Results
Subacute		
<i>Inhalation</i>		
LOEL	Dog	<= 10.4 mg/kg/day, 4 weeks Pharmacological effects
		<= 9 mg/kg/day, 4 weeks Pharmacological effects
	Rat	<= 6.9 mg/kg/day, 4 weeks Pharmacological effects
Subchronic		
<i>Inhalation</i>		
LOEL	Dog	<= 13 mcg/kg/day, 39 weeks Pharmacological effects
		<= 11 mcg/kg/day, 13 weeks Pharmacological effects
	Mouse	<= 7 mcg/kg/day, 13 weeks Pharmacological effects
	Rat	<= 24 mcg/kg/day, 13 weeks Pharmacological effects
		<= 20 mcg/kg/day, 26 weeks Pharmacological effects
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
<i>Oral</i>		
LD50	Rat	> 2000 mg/kg
VILANTEROL (CAS 503070-58-4)		
Acute		
<i>Oral</i>		
LD		> 300 mg/kg
Subchronic		
<i>Inhalation</i>		
NOAEL	Dog	62.5 mcg/kg/day, 39 weeks heart, respiratory tract irritation
		9.3 mcg/kg/day, 13 weeks heart, respiratory tract irritation
	Mouse	38200 mcg/kg/day, 13 weeks clinical signs, mortality
	Rat	658 mcg/kg/day, 13 weeks respiratory tract irritation
		58 mcg/kg/day, 26 weeks respiratory tract irritation
NOEL	Dog	< 9.3 mcg/kg/day, 13 weeks adrenergic effects
		< 9.55 mcg/kg/day, 39 weeks adrenergic effects
	Mouse	< 59 mcg/kg/day, 13 weeks adrenergic effects
	Rat	< 56 mcg/kg/day, 13 weeks adrenergic effects
		< 58 mcg/kg/day, 26 weeks adrenergic effects

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Corrosivity	
FLUTICASONE FUROATE	OECD 404 Result: Negative Species: Rabbit Reconstituted Human Epidermis Result: Negative
VILANTEROL	
Irritation Corrosion - Skin: P.I.I. value	
MAGNESIUM STEARATE	0
Serious eye damage/eye irritation	Direct contact with eyes may cause temporary irritation.
Eye	
FLUTICASONE FUROATE	0.05 % Acute Occular irritation Result: Negative Species: Rabbit Read across, Read across, Fluticasone propionate Result: Negative Species: Rabbit Reconstituted Human Corneal Epithelium (HCE) Result: Negative
VILANTEROL	
Eye / Kay and Calandra class - Intact	
MAGNESIUM STEARATE	4 Recovery Period: 2 days
Respiratory or skin sensitization	
Respiratory sensitization	Due to partial or complete lack of data the classification is not possible.
Skin sensitization	This product is not expected to cause skin sensitization.
Sensitization	
VILANTEROL	50 % OECD 429, Vehicle - Dimethyl formamide Result: Negative
FLUTICASONE FUROATE	Read across, Fluticasone propionate Result: Negative Species: Guinea pig
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.
Germ cell mutagenicity: Ames test	
VILANTEROL	ICH S 2 (R1) Result: Negative
Germ cell mutagenicity: Micronucleus	
VILANTEROL	ICH S 2 (R1) Result: Negative
Mutagenicity	
FLUTICASONE FUROATE	Ames Result: Negative Chromosomal aberration assay Result: Negative
VILANTEROL	L5178Y mouse lymphoma thymidine kinase locus assay, GW642444H Result: Negative L5178Y mouse lymphoma thymidine kinase locus assay, GW642444H, DNA damage occurred only at cytotoxic concentrations. Result: Positive Mouse Lymphoma Cell (L5178Y) Assay Result: Negative Rat Micronucleus Assay Result: Negative
FLUTICASONE FUROATE	Rat UDS assay, GW642444H Result: Negative Syrian Hamster Embryo (SHE) cell transformation assay, GW642444H Result: Negative bacterial mutation assay (high throughput fluctuation test), GW642444H Result: Negative
VILANTEROL	

Carcinogenicity

This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Not classifiable as to carcinogenicity to humans. Carcinogenic effects are not expected as a result of occupational exposure.

VILANTEROL

> 10.5 mcg/kg/day ICH S1B - Inhalation, NOAEL
Result: Negative
Species: Rat
Test Duration: 104 weeks
> 6.4 mcg/kg/day ICH S1B - Inhalation, NOAEL
Result: Negative
Species: Mouse
Test Duration: 104 weeks
> 62 mcg/kg/day ICH S1B - Inhalation, Species-specific
Result: Positive
Species: Mouse
Organ: Uterus/ Ovary
Test Duration: 104 weeks
> 84.4 mcg/kg/day ICH S1B - Inhalation, Species-specific
Result: Positive
Species: Rat
Organ: Pituitary/ Ovary
Test Duration: 104 weeks
FLUTICASONE FUROATE
ICH S1B - Inhalation
Result: Negative
Species: Mouse
ICH S1B - Inhalation
Result: Negative
Species: Rat

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity

Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals.

Reproductivity

VILANTEROL

10000 mcg/kg/day Pre- and Post-natal development
Result: No developmental effects observed.
Species: Rat
30 mcg/kg/day Embryo-foetal development, sub-cutaneous administration
Result: NOAEL
Species: Rabbit
300 mcg/kg/day Embryo-foetal development, sub-cutaneous administration
Species: Rabbit
Organ: Skeletal effects
300 mcg/kg/day Embryo-foetal development, sub-cutaneous administration
Species: Rabbit
Organ: open eye
33700 mcg/kg/day Fertility, Male
Result: No adverse effects on fertility.
Species: Rat
37112 mcg/kg/day Fertility, Female
Result: No adverse effects on fertility.
Species: Rat
FLUTICASONE FUROATE
8 mcg/kg/day Embryofetal Development
Result: NOAEL
Species: Rabbit
91 mcg/kg/day Female Fertility / Early Embryonic Development
Result: reduced foetal bodyweight, minor skeletal variations
Species: Rat
VILANTEROL
> 33700 mcg/kg/day Embryo-foetal development
Species: Rat
FLUTICASONE FUROATE
>= 47 mcg/kg/day Embryofetal Development
Result: Maternal weight loss/ Foetal abortion
Species: Rabbit

Reproductivity
FLUTICASONE FUROATE

Male Fertility
Result: No effect
Species: Rat

Specific target organ toxicity - single exposure Heart.

Specific target organ toxicity - repeated exposure May cause damage to organs through prolonged or repeated exposure.

FLUTICASONE FUROATE

Read across, Glucocorticoid
Organ: Adrenals, Immune system, Bone, Eyes

Aspiration hazard Due to partial or complete lack of data the classification is not possible.

Chronic effects Prolonged inhalation may be harmful. May cause damage to organs through prolonged or repeated exposure.

Further information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test Results
FLUTICASONE FUROATE (CAS 397864-44-7)			
Aquatic			
<i>Acute</i>			
Activated Sludge Respiration	IC50	Residential sludge	> 1000 mg/l, 3 hours Nominal, OECD 209
	NOEC	Residential sludge	1000, 3 hours Nominal
Crustacea	EC50	Water flea (Daphnia magna)	> 4.2 mg/l, 48 hours Static renewal test, OECD 202
	NOEC	Water flea (Daphnia magna)	4.2 mg/l, 48 hours Static renewal test
Terrestrial			
<i>Acute</i>			
Earthworm	EC50	Manure worm (Eisenia foetida)	> 1000 mg/kg, 14 days Measured, OECD 207
	NOEC	Manure worm (Eisenia foetida)	1000 mg/kg, 14 days
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
<i>Acute</i>			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
VILANTEROL (CAS 503070-58-4)			
Aquatic			
<i>Acute</i>			
Algae	EC50	Green algae (Pseudokirchneriella subcapitata)	1.33 mg/l, 72 hours Nominal
	NOEC	Algae	0.139 mg/l, 72 hours
<i>Chronic</i>			
Crustacea	LOEC	Water flea (Daphnia magna)	18.25 mg/l, 21 days semi-static test conditions
	NOEC	Daphnia	9.125 mg/l, 21 days
Fish	Growth test LOEC	Fathead minnow (Juvenile Pimephales promelas)	1.62 mg/l, 28 days Nominal
	Growth test NOEC	Fish	0.54 mg/l, 28 days

* Estimates for product may be based on additional component data not shown.

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

FLUTICASONE FUROATE 0 %, 28 days Modified MITI (II) Test., Activated sludge

MAGNESIUM STEARATE 77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-soil)

FLUTICASONE FUROATE 2 - 3 %, 64 days, Soil

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

FLUTICASONE FUROATE 2.61 (Measured).

VILANTEROL 1.39

Bioconcentration factor (BCF)

MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

FLUTICASONE FUROATE 3.6 - 4.2 Measured

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general

Distribution

Octanol/water distribution coefficient log DOW

VILANTEROL 0.09 Measured., pH 5

1.35 Measured., pH 7

1.39 Measured., pH 9

Other adverse effects Not available.

13. Disposal considerations

Disposal instructions

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable regulations.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Waste from residues / unused products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as a dangerous good.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

15. Regulatory information

US federal regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No
 Delayed Hazard - Yes
 Fire Hazard - No
 Pressure Hazard - No
 Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous chemical No

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations**Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List**

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA) Not regulated.

US state regulations**US. California Controlled Substances. CA Department of Justice (California Health and Safety Code Section 11100)**

Not listed.

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

Not listed.

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed.

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

Country(s) or region	Inventory name	On inventory (yes/no)*
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)
A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date	03-11-2015
Revision date	03-11-2015
Version #	03
Further information	HMIS® is a registered trade and service mark of the NPCA.
HMIS® ratings	Health: 2* Flammability: 0 Physical hazard: 0
NFPA ratings	Health: 2 Flammability: 0 Instability: 0
References	GSK Hazard Determination
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.
Revision Information	This document has undergone significant changes and should be reviewed in its entirety.